[HTML][HTML] Targeting EZH2 in cancer therapy
M Yamagishi, K Uchimaru - Current opinion in oncology, 2017 - journals.lww.com
M Yamagishi, K Uchimaru
Current opinion in oncology, 2017•journals.lww.comTargeting EZH2 in cancer therapy : Current Opinion in Oncology Targeting EZH2 in cancer
therapy : Current Opinion in Oncology Log in or Register Subscribe to journalSubscribe Get
new issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation
Subscribe Register Login Articles & Issues For Authors Journal Info Advanced Search
September 2017 - Volume 29 - Issue 5 Previous Article Next Article INNOVATIVE AGENTS
AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Targeting …
therapy : Current Opinion in Oncology Log in or Register Subscribe to journalSubscribe Get
new issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation
Subscribe Register Login Articles & Issues For Authors Journal Info Advanced Search
September 2017 - Volume 29 - Issue 5 Previous Article Next Article INNOVATIVE AGENTS
AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Targeting …
Summary
The EZH2-mediated epigenome and subsequent transcriptome define cellular identity. Effective and specific strategies for the manipulation of EZH2/PRC2 may lead to the development of more precise cancer medicines.
Lippincott Williams & Wilkins